{"aliases":[{"type":"CodeName","name":"CDP 870"},{"type":"CodeName","name":"PHA-738144"},{"type":"USBrandName","name":"Cimzia"},{"type":"Abbreviation","name":"CZP"},{"type":"CodeName","name":"CDP870"},{"type":"CASRegistryName","name":"428863-50-7"}],"definition":{"html":"A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile.","text":"A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile."},"drugInfoSummaryLink":null,"nciConceptId":"C80972","nciConceptName":"Certolizumab Pegol","termId":791843,"name":"certolizumab pegol","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"certolizumab-pegol"}